Cargando…

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049870/ https://www.ncbi.nlm.nih.gov/pubmed/21135857 http://dx.doi.org/10.1038/leu.2010.226

Ejemplares similares

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients
por: Dutt, Shelley B., et al.
Publicado: (2017)

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2017)

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

mTOR inhibitor everolimus reduces invasiveness of melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
por: Silic-Benussi, Micol, et al.
Publicado: (2023)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
por: Kordes, S., et al.
Publicado: (2015)

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
por: Bernard, Sarah, et al.
Publicado: (2021)

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia
por: Sfeir, J G, et al.
Publicado: (2017)

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2019)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
por: Gennatas, Constantine, et al.
Publicado: (2012)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
por: Taglieri, Ludovica, et al.
Publicado: (2023)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
por: Porrata, Luis F., et al.
Publicado: (2015)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
por: Tan, Peter, et al.
Publicado: (2016)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
por: Castellino, A., et al.
Publicado: (2018)

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2020)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_929rdva2i79dcu671ktmlnci66